Abatacept in B7-1–Positive Proteinuric Kidney Disease | Zendy

Chih Chuan Yu | Zendy; Alessia Fori | Zendy; Astrid Weins | Zendy; Samy Hakroush | Zendy; Dony Maiguel | Zendy; Junichiro Sageshima | Zendy; Linda Chen | Zendy; Gaetano Ciancio | Zendy; Mohd Hafeez Faridi | Zendy; Daniel Behr | Zendy; Kirk N. Campbell | Zendy; Jer Ming Chang | Zendy; Hung Chun Chen | Zendy; Jun Oh | Zendy; Christian Faul | Zendy; M. Amin Arnaout | Zendy; Paolo Fiorina | Zendy; Vineet Gupta | Zendy; Anna Greka | Zendy; George W. Burke | Zendy; Peter Mündel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abatacept in B7-1–Positive Proteinuric Kidney Disease

Author(s) -

Chih Chuan Yu,

Alessia Fori,

Astrid Weins,

Samy Hakroush,

Dony Maiguel,

Junichiro Sageshima,

Linda Chen,

Gaetano Ciancio,

Mohd Hafeez Faridi,

Daniel Behr,

Kirk N. Campbell,

Jer Ming Chang,

Hung Chun Chen,

Jun Oh,

Christian Faul,

M. Amin Arnaout,

Paolo Fiorina,

Vineet Gupta,

Anna Greka,

George W. Burke,

Peter Mündel

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1304572

Subject(s) - abatacept , medicine , proteinuria , focal segmental glomerulosclerosis , kidney transplantation , nephrotic syndrome , immunology , transplantation , rituximab , urology , kidney , antibody

Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research